OPKO Health to Sell Lab Testing Unit to Labcorp for $722 Million

What happened

OPKO Health, Inc., a Miami-based pharmaceutical and diagnostics company, disclosed in a Form 8-K filed October 15, 2026 that it entered into an Asset Purchase Agreement dated October 14, 2026 with Laboratory Corporation of America Holdings, the company commonly known as Labcorp.

Under the agreement, OPKO and its wholly owned subsidiary BioReference Health, LLC will sell certain assets of BioReference's clinical and anatomic pathology laboratory testing business to Labcorp. According to the filing, the assets include testing services focused on clinical and women's health, urology, and corrections, as well as OPKO's proprietary 4Kscore prostate cancer test.

Labcorp agreed to pay $722 million in cash at closing, subject to adjustments based on the business's revenue at closing. Labcorp also agreed to pay up to an additional $150 million in cash over a period of up to ten years, tied to revenue generated from Labcorp's sales of the 4Kscore test.

The filing states the deal is not subject to a financing condition. It requires termination or expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act, along with other customary closing conditions. The parties may terminate if the transaction has not closed by April 14, 2027, subject to extension by mutual agreement. If the agreement is terminated in specified circumstances related to a failure to obtain antitrust or other government approvals, Labcorp would owe OPKO a $28,880,000 termination fee.

Market reaction

OPKO's shares closed at $1.61 on the event date, up 17.52% from the previous close of $1.37, according to the price data.

Volume was 55,248,442 shares, or roughly 16.8 times the average volume of 3,284,202. That is about 12 standard deviations above the average, a statistically extreme reading. The filing does not attribute a cause to the price and volume move.

The company and the assets being sold

OPKO Health is a Delaware-incorporated company whose common stock trades on the Nasdaq Global Select Market under the ticker OPK. Its registered address is 4400 Biscayne Blvd., Miami, Florida. The filing does not describe OPKO's business beyond the assets involved in this transaction.

BioReference Health is a wholly owned OPKO subsidiary that runs laboratory testing operations. The assets being sold include clinical and anatomic pathology testing. Anatomic pathology is the branch of lab medicine that examines tissue samples, such as biopsies, under a microscope; clinical pathology covers tests run on blood, urine and other body fluids.

The 4Kscore is described in the filing as OPKO's proprietary prostate cancer test, and the deal gives Labcorp the right to sell it. Labcorp is a large, publicly traded laboratory testing company headquartered in Burlington, North Carolina, and the buyer here.

What this means

A Form 8-K is the current report a U.S. public company must file with the SEC when certain specified events occur — the list of triggering events is in the instructions to the form. Here the company checked Item 1.01, which covers entering into a material definitive agreement, and Item 9.01, which covers the financial statements and exhibits that accompany the report. The obligation is triggered by the event itself, not by any SEC judgment that the news matters. It is the mechanism that puts a major contract on the public record while the deal is still pending.

This particular 8-K put the actual Asset Purchase Agreement on file as Exhibit 2.1. Attorneys negotiate these agreements with representations, warranties, covenants and indemnification provisions — contractual promises about the state of the business, what each side will and will not do before closing, and who pays if a promise turns out to be false. The filing warns that these clauses are written to allocate risk between the parties, not to describe the companies as they really are, which is why readers are cautioned not to treat them as factual statements about OPKO or Labcorp.

The deal mechanics turn on two things. First is cash at closing: $722 million, subject to adjustments based on revenue at closing, meaning the figure could move up or down depending on what the business actually produces before the deal is done. Second is contingent consideration: up to $150 million over ten years tied to Labcorp's 4Kscore sales. That kind of payment, sometimes called an earnout, is how a buyer and seller bridge the gap between the price today and the price if the asset performs. It is not guaranteed money.

What happens next is set by the agreement rather than by any forecast. The transaction needs HSR clearance — the antitrust waiting period under the Hart-Scott-Rodino Act, in which the Federal Trade Commission and Department of Justice review certain mergers and acquisitions before they close. There is an outside date of April 14, 2027, after which either party may walk away unless they mutually agree to extend. The explicit termination fee of $28,880,000 payable by Labcorp in certain regulatory-failure scenarios is a common feature of large deals: it compensates the seller if the buyer cannot clear antitrust review, while keeping a seller from simply collecting a windfall if the deal fails.

The agreement also contains a no-shop clause. OPKO and BioReference have agreed not to solicit or negotiate alternative transactions for the business, which protects the buyer's deal while the antitrust review runs. The filing states closing is not conditioned on financing, meaning Labcorp does not need to line up a loan or raise money first.

The filing itself does not say why OPKO decided to sell the business, and the provided sources give no stated rationale. The transaction remains subject to closing conditions, so the sale is agreed but not complete.